Thursday September 10, 2026
7:14 PM CT – 8:14 PM CT Dinner/CME Meeting
George R. Brown Convention Center
1001 Avenida de las Americas
Houston, TX
Meeting Room: Level 3 Grand Ballroom C (Theater 3)
PROGRAM FEATURES
- Interactive, case-based learning environment
- Create your own personalized poster
PRESENTING FACULTY
 |
Prithviraj Bose, MD Professor, Department of Leukemia Co-Section Head, MPN Section UT MD Anderson Cancer Center Houston, Texas |
 |
Pankit Vachhani, MD Associate Prof of Medicine Chief – Leukemia service Director – Strategic Outreach and Events Medical Director – Clinical Research Unit (CRU) University of Alabama at Birmingham Birmingham, Alabama |
PROGRAM OVERVIEW
This CME activity provides clinicians with evidence-based approaches to optimize management of anemia in myelofibrosis (MF). Participants will examine current guideline recommendations for sequencing anemia-directed therapies, review safety and efficacy data for approved and emerging agents, and evaluate patient characteristics predictive of benefit from early frontline anemia-sparing strategies. The program emphasizes individualized decision-making to improve outcomes, reduce toxicity, and deliver timely, patient-centered care across diverse clinical scenarios and treatment settings.
TARGET AUDIENCE
This program is designed to address the educational needs of the multidisciplinary hematology-oncology team, including hematologists, pathologists, nurses, and other healthcare professionals working together to address the needs of patients with anemia due to MF.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Apply guideline recommendations for the management and sequencing of anemia-directed therapies for patients suffering from anemia associated with MF
- Integrate the safety and efficacy data for emerging and approved anemia targeting agents in MF to inform treatment strategies
- Assess patient characteristics that could predict benefit from early frontline anemia-sparing therapies in MF to provide appropriate and timely treatment
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of up to 1.0 ANCC contact hours.
ACCME INNOVATION PARTNER – US Learners Only
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event Staff will be glad to assist you with any special needs (eg, physical, dietary, etc). Please contact Med Learning Group prior to the live event at [email protected]
